CatalYm GmbH Alternatives & Competitors
12 companies similar to CatalYm GmbH — Developing innovative immunotherapies to transform cancer patients’ lives by eng...
Companies similar to CatalYm GmbH
Pyxis Oncology
Charting a course to therapeutics for difficult-to-treat cancer.
Bicara Therapeutics
Pioneering bifunctional antibodies for targeted tumor modulation
OXFORD VACMEDIX UK LIMITED
Developing therapeutic cancer vaccines using ROP technology
NBE-Therapeutics AG
Next generation antibody drug conjugates
Rival Readout
Competing with CatalYm GmbH? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Imvax, Inc.
Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-deriv...
Crossbow Therapeutics, Inc
Established antibody engineering to target the untapped universe of intracellular cancer t...
Xilio Therapeutics, Inc.
Focused on harnessing the immune system to achieve deep and durable clinical responses to...
Kite Pharma
At Kite, a Gilead Company, our singular focus is cell therapy to treat and cure cancer.
Neogene Therapeutics
Pushing the frontier by pioneering next-generation engineered T cell receptor therapies fo...
Surface Oncology Inc.
#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2...
Macomics
Macrophage Biology Revealed:Developing breakthrough approaches to macrophage activity to c...
About CatalYm GmbH
CatalYm GmbH, founded in 2016, is a Germany-based company deeply embedded in the Biotechnology and Health Care sectors. The company's mission—"Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems"—captures its commitment to advancing medical treatments through r...
Development of immunotherapies targeting GDF-15, Conducting clinical trials for cancer treatment, Advancing drug candidates for cachexia associated with cancer
Oncologists, Cancer Centers, Pharmaceutical Companies, Healthcare Providers
Immunotherapy, Cancer Treatment, Oncology, Antibody Development, Tumor Microenvironment, GDF-15 Targeting, Solid Tumors, Neutralizing Antibodies, Immune System Engagement, Placental Factor Overproduction, CT-002 Program, Clinical Proof-of-Concept, Therapeutic Innovation, Tumor-Specific Treatment
B2B, B2B2C
Licensing, Product Sales, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around CatalYm GmbH: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at CatalYm GmbH on 28 May 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 11 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.